Contact CFFC


Clinical Trial Alerts – August 2019

Cystic Fibrosis Foundation issued the following clinical trial alert in the month of August.

August 7, 2019

Study to evaluate the effects of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (PROMISE)

Status: Enrolling

Description: This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in people with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects people with CF across many different aspects of the disease.

Age: 12 Years and Older

Mutation: Two Copies F508del or One Copy F508del

Fev1% Predicted: No FEV1 Limit

Number of Visits: 6

Length of Participation: 2 years link:

Comments are closed.